Arkema

Sustained profitability despite lower sales prices

14/05/24 -"Sales in the Q1 declined as anticipated, but adjusted EBITDA demonstrated greater resilience. The figures were mixed compared to the consensus (sales: -2.0%; adjusted EBITDA: +2.6%; adjusted EPS: ..."

PDF page sample
Pages
63
Language
English
Published on
14/05/24
Download
You may also be interested by these reports :
15/07/25
Positive momentum fading, time to collect profit
15/07/25
Solvay has confirmed our cautious view by cutting the FY EBITDA guidance to €880-930m, down from the previous target of the lower half of the ...
15/07/25
We are increasingly optimistic about working capital management in the coming years, anticipating higher inflows. However, we have reduced the ...
14/07/25
Givaudan remains a preferred defensive option ahead of the 1H25E results

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO